CalciMedica Reports Third Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
Globe Newswire•10/11/2026•07:00 ET
0
Key Highlights
- ➤Cash $13.8 million, runway expected into second half of 2027
- ➤Auxora Phase 1b PH data anticipated in mid-2027
- ➤CM5480 IND submission anticipated in mid-2027
- ➤FDA aligned with Auxora Phase 2b acute pancreatitis trial design
- ➤Net loss narrowed to $1.7 million from $7.8 million year-over-year
Expert Statements
Rachel Leheny, Chief Executive Officer of CalciMedica
“We continue to advance our pulmonary hypertension strategy, with data from the Auxora Phase 1b proof-of-concept trial in PH and the CM5480 IND submission both anticipated in mid-2027. Preclinical models suggest CRAC channel inhibitors may provide a differentiated approach in pulmonary hypertension by targeting multiple disease drivers, including right ventricular dysfunction, which is the principal cause of mortality and not directly targeted by existing therapies. In acute pancreatitis, FDA alignment on a trial with a patient enrichment strategy and endpoints provides a clear framework for the next stage of development in a disease with no approved therapies. We expect multiple meaningful catalysts over the next 12 months.”
Auxora Phase 1b proof-of-concept data in pulmonary hypertension (PH) and CM5480 IND submission both anticipated in mid-2027
Cash, cash equivalents and short-term investments of $13.8 million as of September 30, 2026; cash expected to fund current operating plan into the second half of 2027
Get started
Create a free account to read the full story.